NTRK1 and intrahepatic cholangiocarcinoma: Here, we highlight the usage of the first-line chemotherapy CisGem, the receptor tyrosine kinase inhibitor lenvatinib in combination with the anti-PD-1 drug tislelizumab for this advanced ICC patient after intense discussion in MDT.